Page last updated: 2024-12-06

2-Oxo-4-phenylbutyric acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID69732
CHEMBL ID16281
CHEBI ID181422
SCHEMBL ID258545

Synonyms (35)

Synonym
710-11-2
2-oxo-4-phenylbutyric acid
CHEBI:181422
2-oxo-4-phenylbutanoic acid
2-oxo-4-phenyl-butanoic acid
benzenebutanoic acid, alpha-oxo-
2-oxo-4-phenyl-butyric acid
bdbm50125828
CHEMBL16281 ,
einecs 211-916-7
2-oxo-4-phenylbutanoate
C20327
AKOS005174543
FT-0632864
SCHEMBL258545
DTXSID10221224
4-phenyl-2-oxobutyric acid
4-phenyl-2-oxobutanoic acid
PPKAIMDMNWBOKN-UHFFFAOYSA-N
4-phenyl-2-ketobutanoic acid
2-oxo-4-phenyl butyric acid
oxobenzenebutanoic acid
benzylpyruvic acid
W-104537
CS-W019322
O0389
2-oxo-4-phenyl-butyric acid, aldrichcpr
mfcd00969471
AC-3539
2-oxo-4-phenylbutanoicacid
DS-3613
2-oxo-4-phenyl-butyricacid
benzenebutanoic acid, a-oxo-
EN300-143516
Z1201620725

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" These mt-QSARs offer also a good opportunity to construct drug-drug Complex Networks (CNs) that can be used to explore large and complex drug-viral species databases."( Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E, 2009
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzenesAny benzenoid aromatic compound consisting of the benzene skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Polymerase acidic proteinInfluenza A virus (A/Puerto Rico/8/1934(H1N1))IC50 (µMol)500.00001.88004.68805.8600AID160322; AID666158
RNA-directed RNA polymerase IC50 (µMol)50.00000.01902.52798.8000AID166725
ALK tyrosine kinase receptorHomo sapiens (human)IC50 (µMol)500.00000.00010.310710.0000AID666158
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (20)

Processvia Protein(s)Taxonomy
protein autophosphorylationALK tyrosine kinase receptorHomo sapiens (human)
signal transductionALK tyrosine kinase receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayALK tyrosine kinase receptorHomo sapiens (human)
phosphorylationALK tyrosine kinase receptorHomo sapiens (human)
hippocampus developmentALK tyrosine kinase receptorHomo sapiens (human)
adult behaviorALK tyrosine kinase receptorHomo sapiens (human)
swimming behaviorALK tyrosine kinase receptorHomo sapiens (human)
peptidyl-tyrosine autophosphorylationALK tyrosine kinase receptorHomo sapiens (human)
regulation of apoptotic processALK tyrosine kinase receptorHomo sapiens (human)
protein autophosphorylationALK tyrosine kinase receptorHomo sapiens (human)
neuron developmentALK tyrosine kinase receptorHomo sapiens (human)
negative regulation of lipid catabolic processALK tyrosine kinase receptorHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityALK tyrosine kinase receptorHomo sapiens (human)
regulation of dopamine receptor signaling pathwayALK tyrosine kinase receptorHomo sapiens (human)
response to environmental enrichmentALK tyrosine kinase receptorHomo sapiens (human)
energy homeostasisALK tyrosine kinase receptorHomo sapiens (human)
positive regulation of dendrite developmentALK tyrosine kinase receptorHomo sapiens (human)
regulation of neuron differentiationALK tyrosine kinase receptorHomo sapiens (human)
regulation of cell population proliferationALK tyrosine kinase receptorHomo sapiens (human)
multicellular organism developmentALK tyrosine kinase receptorHomo sapiens (human)
positive regulation of kinase activityALK tyrosine kinase receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
protein tyrosine kinase activityALK tyrosine kinase receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityALK tyrosine kinase receptorHomo sapiens (human)
protein bindingALK tyrosine kinase receptorHomo sapiens (human)
ATP bindingALK tyrosine kinase receptorHomo sapiens (human)
heparin bindingALK tyrosine kinase receptorHomo sapiens (human)
receptor signaling protein tyrosine kinase activator activityALK tyrosine kinase receptorHomo sapiens (human)
identical protein bindingALK tyrosine kinase receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
extracellular regionPolymerase acidic proteinInfluenza A virus (A/Puerto Rico/8/1934(H1N1))
plasma membraneALK tyrosine kinase receptorHomo sapiens (human)
plasma membraneALK tyrosine kinase receptorHomo sapiens (human)
extracellular exosomeALK tyrosine kinase receptorHomo sapiens (human)
protein-containing complexALK tyrosine kinase receptorHomo sapiens (human)
receptor complexALK tyrosine kinase receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID392531Antiviral activity against influenza virus2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID160322Inhibitory concentration against cap-dependent endonuclease activity of influenza virus RNP2003Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7
Use of a pharmacophore model to discover a new class of influenza endonuclease inhibitors.
AID1597857Inhibition of Staphylococcus aureus pyruvate carboxylase expressed in Escherichia coli BL21(DE3) assessed as FVB-OAA adduct formation using pyruvate as substrate by Fast violet B assay2019Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
Evaluation of α-hydroxycinnamic acids as pyruvate carboxylase inhibitors.
AID166725Inhibitory activity against Hepatitis C virus RNA dependent RNA polymerase nonstructural protein 5B2004Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1
Discovery of alpha,gamma-diketo acids as potent selective and reversible inhibitors of hepatitis C virus NS5b RNA-dependent RNA polymerase.
AID666158Inhibition of cap 1 ALMV primed Influenza transcriptase1994Antimicrobial agents and chemotherapy, Dec, Volume: 38, Issue:12
Inhibition of cap (m7GpppXm)-dependent endonuclease of influenza virus by 4-substituted 2,4-dioxobutanoic acid compounds.
AID392510Antiviral activity against Hepatitis C virus2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's3 (60.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.87 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]